TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25740262
Drug: Daclatasvir (DCV)
DrugBank: Daclatasvir (DB09102)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Daclatasvir (DCV) multiple oral doses of 1/10/100 mg once-daily for 14 days
Study: 25740262
Drug: Asunaprevir (ASV)
Normalized name: asunaprevir
DrugBank: Asunaprevir (DB11586)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Asunaprevir (ASV) multiple oral doses of 200/400/600 mg every 12 hours for 14 days
Study: 15303633
Drug: Levofloxacin 500
Normalized name: levofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin 500 mg once daily for 7 days
Study: 1641600
Drug: erythromycin stearate
Normalized name: Erythromycin Stearate
Approvals — FDA: no, EMA: no, PMDA: no
Description: erythromycin stearate 500 mg b.i.d.
Study: 20710083
Drug: Cervical manipulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cervical manipulation (specific dosage and duration not provided)
Study: 17981886
Drug: Comparison between
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison between IV-S and IV-G
Study: 17130263
Drug: Olmesartan (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan (40 mg) for 16 weeks
Study: 11552355
Drug: McKenzie-concept, mobilisation
Approvals — FDA: no, EMA: no, PMDA: no
Description: McKenzie-concept, mobilisation therapies, traction
Study: 11552355
Drug: Pain reducing
Normalized name: Dermoplast Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pain reducing physical therapies (cold or electrotherapy)
Study: 11552355
Drug: Non-steroidal anti-inflammatory
Normalized name: Non-steroidal anti-inflammatory agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-steroidal anti-inflammatory drugs, analgesics, muscle relaxants
Study: 9382981
Drug: Interferon‐α therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon‐α therapy
Study: 8037993
Drug: Nitrates (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrates (40 mg isosorbide dinitrate twice daily)
Study: 31281988
Drug: ONO-4474 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: ONO-4474 (100 mg, orally, twice daily for 28 days)
Study: 24693945
Drug: Whole body
Normalized name: MaxiVision Whole Body Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole body vibration exercise twice a week for 3 months
Study: 24693945
Drug: General exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: General exercise twice a week for 3 months
Study: 20632193
Drug: lafutidine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: lafutidine (20 mg/day)
Study: 20632193
Drug: famotidine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: famotidine (40 mg/day)
Study: 17554249
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (20 mg/day elemental zinc in multivitamin syrup for 2 weeks)
Study: 17554249
Drug: Multivitamin syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multivitamin syrup without zinc (control)
Study: 2276389
Drug: omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: omeprazole 20 mg once daily
Study: 2276389
Drug: cimetidine 400
Normalized name: cimetidine 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: cimetidine 400 mg b.d.
Study: 26475246
Drug: Intravenous fluid
Normalized name: Intravenous fluid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous fluid bolus administration guided by noninvasive cardiac output monitor after passive leg-raising maneuver
Study: 23141856
Drug: High-intensification intravenous
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-intensification intravenous diuretic therapy
Study: 23141856
Drug: Low-intensification intravenous
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-intensification intravenous diuretic therapy
Study: 20415693
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose combination (sitagliptin 50 mg b.i.d. + metformin 1000 mg b.i.d.)
Study: 20415693
Drug: Lower dose
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower dose combination (sitagliptin 50 mg b.i.d. + metformin 500 mg b.i.d.)
Study: 20415693
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose metformin (metformin 1000 mg b.i.d.)
Study: 20415693
Drug: Lower dose
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower dose metformin (metformin 500 mg b.i.d.)
Study: 20415693
Drug: Sitagliptin monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin monotherapy (sitagliptin 100 mg q.d.)
Study: 20415693
Drug: Placebo/metformin (switched
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo/metformin (switched to metformin monotherapy uptitrated to 1000 mg b.i.d.)
Study: 17086017
Drug: Hydrolyzed whey
Normalized name: amino acids/hydrolyzed collagen/hydrolyzed whey 15 gram-100 kcal/30 mL ORAL LIQUID (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrolyzed whey protein (20 g/d)
Study: 17086017
Drug: Unmodified whey
Normalized name: whey protein hydrolysate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unmodified whey protein (control treatment)
Study: 10486435
Drug: Film-coated tablet
Normalized name: ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Film-coated tablet formulation of risedronate
Study: 10486435
Drug: Gelatin capsule
Normalized name: Gelatin Capsules
DrugBank: Gelatin (DB11242)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gelatin capsule formulation of risedronate
Study: 6374946
Drug: Tube gastrostomy
Normalized name: Sus scrofa fallopian tube preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tube gastrostomy (Group G)
Study: 30351426
Drug: Personalized antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized antibiotic strategies (COMPASS)
Study: 26846336
Drug: Methods designed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methods designed to enhance self-efficacy (treatment)
Study: 25231491
Drug: Ketamine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (0.5 or 1 mg/kg)
Study: 17631326
Drug: Intravesical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical therapy (control for group 2)
Study: 7817931
Drug: Sotalol (alternate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotalol (alternate therapy group)
Study: 2266432
Drug: Cross-covering senior
Normalized name: Red Cross Canker Sore
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cross-covering senior resident (CC group)
Study: 543911
Drug: mezlocillin (Baypen)
Normalized name: mezlocillin
DrugBank: Mezlocillin (DB00948)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: mezlocillin (Baypen) at a daily dosage of 2 x 5 g or 3 x 5 g
Study: 28397833
Drug: Short-term oral
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term oral immunotherapy (OIT) with Cry j 1-galactomannan conjugate
Study: 26952142
Drug: Standardized extract
Normalized name: Spring Valley Olive Leaf Standardized Extract 150mg Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized extract of Prunus mume (150 mg)
Study: 21940716
Drug: Paricalcitol (injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paricalcitol (injection and capsules)
Study: 18198986
Drug: Fenofibrate treatment
Normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fenofibrate treatment for 3 months
Study: 15188947
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg U/day of Ultrasome-CoQ10 for 3 months
Study: 11151290
Drug: Diet only
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet only treatment group
Study: 9343478
Drug: Differentiated treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Differentiated treatment based on clinical sleep disturbances (including amitriptylin, imipramine, diazepam, nootropic drugs)
Study: 3537823
Drug: Naftidrofuryl treatment
Normalized name: naftidrofuryl
DrugBank: Naftidrofuryl (DB13588)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naftidrofuryl treatment
Study: 31464623
Drug: Treatment effect
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment effect at endline
Study: 31464623
Drug: Baseline treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline treatment effect
Study: 25588410
Drug: Midwife oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midwife oral assessment and referral to private/public/health fund dental services pathway (Intervention Group 1)
Study: 25588410
Drug: Midwife oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midwife oral assessment and referral to local free public dental services pathway (Intervention Group 2)
Study: 25588410
Drug: Oral health
Normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral health promotional material only (Control Group)
Study: 21672049
Drug: 20 ng/ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ng/ml tacrolimus
Study: 16501756
Drug: Cognitive-behavioral approach
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral approach without nicotine replacement therapy (GB)
Study: 16501756
Drug: Cognitive-behavioral approach
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral approach with nicotine replacement therapy (GBA)
Study: 10695262
Drug: Exercise training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise training (attending classes at least twice a week for 25 weeks, each lasting two hours)
Study: 10695262
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (attending recreational classes twice a month)
Study: 9359554
Drug: Cardioselective beta
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardioselective beta blockers
Study: 8096545
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg dose of ebastine syrup
Study: 8096545
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg dose of ebastine syrup
Study: 3805797
Drug: Regimen II
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen II (Dapsone, rifampicin, and clofazimine 100 mg on alternate days)
Study: 28641216
Drug: PEGASUS (8-session
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEGASUS (8-session treatment)
Study: 24351088
Drug: Active waiting
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active waiting list control group with delayed treatment
Study: 20514964
Drug: Intravenous clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous clonidine 1 microg/kg (group C1, n=39)
Study: 20514964
Drug: Intravenous clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous clonidine 2 microg/kg (group C2, n=41)
Study: 16623401
Drug: Minimal low-flow
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimal low-flow anesthesia (LFA) at 0.3 mL/min
Study: 16623401
Drug: Semi-closed high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semi-closed high flow anesthesia (HFA) at 2 L/min
Study: 14763696
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (10 mg/kg bolus IV, followed by 1 mg/kg/hour continuous infusion for 10 hours)
Study: 14763696
Drug: Placebo (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (20 mL saline IV)
Study: 7871655
Drug: Pikamilon administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pikamilon administration
Study: 2893187
Drug: Zidovudine (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zidovudine (250 mg 6‐hourly, 500 mg 6‐hourly, or 500 mg 12‐hourly)
Study: 6145726
Drug: Alprazolam (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam (2 mg)
Study: 30286443
Drug: Dronabinol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dronabinol (10 mg and 30 mg)
Study: 30286443
Drug: CBD (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBD (750 mg)
Study: 30286443
Drug: CBD (1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBD (1500 mg)
Study: 30286443
Drug: CBD (4500
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBD (4500 mg)
Study: 30286443
Drug: CBD (1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBD (1500 mg and 4500 mg)
Study: 21541241
Drug: Intermittent chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent chemotherapy with gemcitabine (1250 mg/m² on days 1 and 4), cisplatin (75 mg/m² on day 2), and erlotinib (150 mg daily on days 5-15, followed by maintenance erlotinib)
Study: 21541241
Drug: Intermittent chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent chemotherapy with gemcitabine, cisplatin, and erlotinib
Study: 19541016
Drug: Amino acid
Normalized name: Amino Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid infusion (0.067 g kg(‐1) h(‐1))
Study: 17944739
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (botox and saline)
Study: 2086423
Drug: Retrobulbar anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retrobulbar anesthesia (RBA) with 5 ml of bupivacaine/lidocaine mixture with adrenaline
Study: 678373
Drug: Existing practice
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Existing practice of non-depolarizing neuromuscular blocking drugs
Study: 31246882
Drug: Cognitive-Behavioral Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-Behavioral Therapy for Insomnia (CBT-I)
Study: 29761313
Drug: Yisui Shengxue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yisui Shengxue Granules (12 g/bag three times a day) for 3 months
Study: 27456034
Drug: sarpogrelate in
Normalized name: Sarpogrelate
DrugBank: Sarpogrelate (DB12163)
Approvals — FDA: no, EMA: no, PMDA: no
Description: sarpogrelate in addition to aspirin
Study: 15270891
Drug: Topical photodynamic
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical photodynamic therapy with methyl aminolaevulinate
Study: 31365437
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy adapted for cognitive impairments (CBT‐ABI), 9 sessions
Study: 27578124
Drug: High-dose vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vitamin E supplementation (1200 IU/d for 12 weeks)
Study: 18403134
Drug: Atomoxetine (25-100mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atomoxetine (25-100mg daily)
Study: 10802078
Drug: Glyceryl trinitrate
Normalized name: Glyceryl trinitrate
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glyceryl trinitrate patches, 0.1 mg/h
Study: 8803306
Drug: Leuprorelin acetate
Normalized name: Leuprorelin acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Leuprorelin acetate depot (LA) 3.75 mg injected subcutaneously every 28 days
Study: 8803306
Drug: Danazol 800
Normalized name: Danazol
DrugBank: Danazol (DB01406)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Danazol 800 mg daily oral dose
Study: 1320563
Drug: Nedocromil sodium
Normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nedocromil sodium (two puffs qid 2 mg/puff)
Study: 31053215
Drug: Imagery Rehearsal
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imagery Rehearsal (IR) + Cognitive Behavioral Therapy for Insomnia (CBT‐I)
Study: 26974539
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of febuxostat 40-mg tablet
Study: 26974539
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of febuxostat 40-mg tablet
Study: 26974539
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of febuxostat 80-mg tablet
Study: 26974539
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of febuxostat 80-mg tablet
Study: 21546512
Drug: Two-quadrant technique
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-quadrant technique (5 ml inferonasal and 5 ml superotemporal injection of 50:50 mixture of 2% lidocaine and 0.5% bupivacaine with 150 IU hyaluronidase)
Study: 21546512
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard 5 ml single inferonasal injection of 50:50 mixture of 2% lidocaine and 0.5% bupivacaine with 150 IU hyaluronidase)
Study: 17034605
Drug: Vaginal cone
Normalized name: Pinus strobus cone extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal cone therapy
Study: 17245662
Drug: Treatment resource
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment resource information package (Control)
Study: 24028643
Drug: Temazepam 7.5
Normalized name: temazepam 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temazepam 7.5 mg
Study: 12826988
Drug: Temazepam 15
Normalized name: temazepam 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temazepam 15 mg
Study: 9543434
Drug: Monotherapy or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy or combination therapy with ritonavir
Study: 9543434
Drug: Monotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with ritonavir or combination therapy with ritonavir and zidovudine
Study: 2448358
Drug: terfenadine (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: terfenadine (120 mg, twice daily for 3 days)
Study: 29606104
Drug: Ubiquinol and/or
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ubiquinol and/or D-ribose administered for 12 weeks
Study: 27252841
Drug: Sildenafil 20
Normalized name: sildenafil 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil 20 mg 3 times a day
Study: 25527071
Drug: Tenofovir gel
Normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tenofovir gel provision through family planning services
Study: 25527071
Drug: Tenofovir gel
Normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tenofovir gel provision through CAPRISA research clinics
Study: 17582225
Drug: 1.7 g
Normalized name: Vaporizer 1.7 gallon
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.7 g DHA and 0.6 g EPA (omega3 group) daily for 6 months
Study: 8994319
Drug: 2 year
Normalized name: Childrens Panadol 5 - 12 Years
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 year old hepatitis A vaccine
Study: 8994319
Drug: newly produced
Normalized name: RECOMBINANT DNA DERIVED B-DOMAIN DELETED PORCINE BLOODCOAGULATION FACTOR VIII ANALOGUE, PRODUCED IN BHK21 CELLS: DES-(753-1418)-BLOOD-COAGULATION FACTOR VIII (PROCOAGULANT COMPONENT) SUS SCROFA, GLYCOSYLATED
Approvals — FDA: no, EMA: no, PMDA: no
Description: newly produced hepatitis A vaccine
Study: 6230296
Drug: Thymostimulin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymostimulin (1 mg/kg/day for seven days; 1 mg/kg/weekly thereafter)
Study: 31257435
Drug: Multifaceted intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multifaceted intervention targeting health professionals' and patients' behaviour regarding antibiotic use.
Study: 23794225
Drug: Denosumab (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denosumab (administered once every 6 months for 36 months)
Study: 22835804
Drug: CHESS+CM (Comprehensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHESS+CM (Comprehensive Health Enhancement Support System + monthly nurse case management via phone)
Study: 22835804
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (treatment as usual plus asthma information)
Study: 20427350
Drug: Chemoradiotherapy (CRT),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoradiotherapy (CRT), cisplatin 40 mg/m² weekly for seven doses plus RT
Study: 17905018
Drug: L‐hyoscyamine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐hyoscyamine 0.5 mg
Study: 10817552
Drug: IL-1Ra 30
Normalized name: IL-1RA
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: IL-1Ra 30 mg/day
Study: 10817552
Drug: IL-1Ra 75
Normalized name: IL-1RA
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: IL-1Ra 75 mg/day
Study: 10817552
Drug: All IL-1Ra
Normalized name: IL-1RA
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: All IL-1Ra treatment groups combined
Study: 6228370
Drug: Propranolol 80
Normalized name: propranolol 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 80 mg orally 2 h before exercise
Study: 6228370
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide 0.216 mg by inhalation 30 min before exercise
Study: 28743370
Drug: Vibration group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vibration group (50Hz, 0.2N or 20g applied on the buccal surface of maxillary canine)
Study: 23635884
Drug: 0.12% chlorhexidine
Normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.12% chlorhexidine gel (CHX)
Study: 16989497
Drug: Barnidipine (10-15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Barnidipine (10-15 mg)
Study: 15284828
Drug: 200 mg/d,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/d, 3 cycles
Study: 15284828
Drug: 200 mg/d,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/d, 6 cycles
Study: 15284828
Drug: 400 mg/d,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg/d, 3 cycles
Study: 10758445
Drug: Epidural clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epidural clonidine (4 microg kg‐1) combined with epidural morphine (40 microg kg‐1)